

In the Abstract:

Page 8, please accept the following clean copy of the amended abstract:

ABSTRACT OF THE DISCLOSURE

B2
The pharmaceutical compositions for treating hyperinsulinemia contain an effective amount of melatonin and/or a chemically modified derivative thereof for inhibition of insulin release. The melatonin and/or chemically modified derivative of melatonin act to inhibit insulin release by influencing the β -cells of the pancreatic islets in a living being suffering from hyperinsulinemia through a melatonin-specific receptor. The effective amount of melatonin and/or chemically modified derivative thereof in the pharmaceutical composition amounts to from 0.01 to 200 mg. The pharmaceutical compositions can be in the form of a tablet or capsule. Alternatively, they can be in a form for subcutaneous injection, such as an ampule, or for transdermal release.

BEST AVAILABLE COPY